127 related articles for article (PubMed ID: 2538689)
21. Medial thalamic injection of opioid agonists: mu-agonist increases while kappa-agonist decreases stimulus thresholds for pain and reward.
Carr KD; Bak TH
Brain Res; 1988 Feb; 441(1-2):173-84. PubMed ID: 2833999
[TBL] [Abstract][Full Text] [Related]
22. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
Ko MC; Johnson MD; Butelman ER; Willmont KJ; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1113-20. PubMed ID: 10565831
[TBL] [Abstract][Full Text] [Related]
23. Ventral pallidal microinjections of receptor-selective opioid agonists produce differential effects on circling and locomotor activity in rats.
Hoffman DC; West TE; Wise RA
Brain Res; 1991 Jun; 550(2):205-12. PubMed ID: 1653084
[TBL] [Abstract][Full Text] [Related]
24. Opioid control of the release of calcitonin gene-related peptide-like material from the rat spinal cord in vivo.
Collin E; Frechilla D; Pohl M; Bourgoin S; Le Bars D; Hamon M; Cesselin F
Brain Res; 1993 Apr; 609(1-2):211-22. PubMed ID: 8389648
[TBL] [Abstract][Full Text] [Related]
25. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat.
Miaskowski C; Taiwo YO; Levine JD
Eur J Pharmacol; 1991 Dec; 205(3):247-52. PubMed ID: 1667910
[TBL] [Abstract][Full Text] [Related]
26. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
27. Irreversible selective blockade of kappa-opioid receptors in the guinea-pig ileum.
Sheehan MJ; Hayes AG; Tyers MB
Eur J Pharmacol; 1986 Sep; 129(1-2):19-24. PubMed ID: 3021476
[TBL] [Abstract][Full Text] [Related]
28. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
[TBL] [Abstract][Full Text] [Related]
29. Opioidergic modulation of voltage-activated K+ currents in magnocellular neurons of the supraoptic nucleus in rat.
Müller W; Hallermann S; Swandulla D
J Neurophysiol; 1999 Apr; 81(4):1617-25. PubMed ID: 10200198
[TBL] [Abstract][Full Text] [Related]
30. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors.
Stein C; Millan MJ; Shippenberg TS; Peter K; Herz A
J Pharmacol Exp Ther; 1989 Mar; 248(3):1269-75. PubMed ID: 2539460
[TBL] [Abstract][Full Text] [Related]
31. Opioid-receptor-mediated inhibition of [3H]dopamine but not [3H]noradrenaline release from rat mediobasal hypothalamus slices.
Heijna MH; Padt M; Hogenboom F; Schoffelmeer AN; Mulder AH
Neuroendocrinology; 1991 Aug; 54(2):118-26. PubMed ID: 1662785
[TBL] [Abstract][Full Text] [Related]
32. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.
Horan P; Taylor J; Yamamura HI; Porreca F
J Pharmacol Exp Ther; 1992 Mar; 260(3):1237-43. PubMed ID: 1312164
[TBL] [Abstract][Full Text] [Related]
33. Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex.
Heijna MH; Padt M; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN
Eur J Pharmacol; 1990 Jun; 181(3):267-78. PubMed ID: 2166675
[TBL] [Abstract][Full Text] [Related]
34. Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes.
Spanagel R; Almeida OF; Shippenberg TS
Eur J Pharmacol; 1994 Oct; 264(2):157-62. PubMed ID: 7851478
[TBL] [Abstract][Full Text] [Related]
35. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
36. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
37. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
38. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys.
Butelman ER; Negus SS; Ai Y; de Costa BR; Woods JH
J Pharmacol Exp Ther; 1993 Dec; 267(3):1269-76. PubMed ID: 8263790
[TBL] [Abstract][Full Text] [Related]
39. Effect of nor-binaltorphimine on the behavior of mice and rats receiving multiple injections of U-50,488.
Cowan A; Murray CW
Prog Clin Biol Res; 1990; 328():303-6. PubMed ID: 2154786
[No Abstract] [Full Text] [Related]
40. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse.
Yajima Y; Narita M; Takahashi-Nakano Y; Misawa M; Nagase H; Mizoguchi H; Tseng LF; Suzuki T
Brain Res; 2000 Apr; 862(1-2):120-6. PubMed ID: 10799676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
